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untreated rats. Cilazapril and candesartan prevented massiveBlocking angiotensin II ameliorates proteinuria and glomeru-
proteinuria, increased creatinine clearance, and amelioratedlar lesions in progressive mesangioproliferative glomerulone-
glomerular and tubulointerstitial injury. These drugs also re-phritis.
duced levels of glomerular protein and cortical mRNA forBackground. The renin-angiotensin system is thought to be
TGF-b and collagen types I and III. Hoe 140 failed to blunt theinvolved in the progression of glomerulonephritis (GN) into
end-stage renal failure (ESRF) because of the observed reno- renoprotective effect of cilazapril. Hydralazine did not exhibit a
protective effects of angiotensin-converting enzyme inhibitors renoprotective effect.
(ACEIs). However, ACEIs have pharmacological effects other Conclusion. These results indicate that ACEIs prevent the
than ACE inhibition that may help lower blood pressure and progression to ESRF by modulating the effects of Ang II via
preserve glomerular structure. We previously reported a new Ang II type 1 receptor on the production of TGF-b and colla-
animal model of progressive glomerulosclerosis induced by gen types I and III, as well as on intrarenal hemodynamics,
a single intravenous injection of an anti-Thy-1 monoclonal but not by either increasing bradykinin activity or reducing
antibody, MoAb 1-22-3, in uninephrectomized rats. Using this blood pressure in this rat model of mesangial proliferative GN.
new model of progressive GN, we examined the hypothesis
that ACEIs prevent the progression to ESRF by modulating
the effects of angiotensin II (Ang II) on the production of
Angiotensin-converting enzyme inhibitors (ACEIs) ef-transforming growth factor-b (TGF-b) and extracellular matrix
components. fectively reduce or even reverse the development of scle-
Methods. We studied the effect of an ACEI (cilazapril) and rotic lesions in animal models of progressive glomerular
an Ang II type 1 receptor antagonist (candesartan) on the sclerosis [1–4]. ACEIs decrease angiotensin II (Ang II)clinical features and morphological lesions in the rat model
generation [5] and increase renal kallikrein activity [6],previously reported. After 10 weeks of treatment with equihy-
plasma and renal kinin levels [7], and urinary kinin excre-potensive doses of cilazapril, cilazapril plus Hoe 140 (a bradyki-
nin receptor B2 antagonist), candesartan, and hydralazine, we tion [8]. Bradykinin selectively dilates the efferent arteri-
examined systolic blood pressure, urinary protein excretion, oles [9] and enhances the formation of nitric oxide and
creatinine clearance, the glomerulosclerosis index, and the tu-
prostacylin [10], to which the renoprotective effect ofbulointerstitial lesion index. We performed a semiquantitative
ACEI may be attributed. In passive Heymann nephritis,evaluation of glomerular immunostaining for TGF-b and colla-
gen types I and III by immunofluorescence study and of these ACEIs reduce proteinuria through their action on the
cortical mRNA levels by Northern blot analysis. kallikrein-kinin system rather than on the renin-angio-
Results. Untreated rats developed massive proteinuria, re- tensin system (RAS) [11–13]. On the other hand, bothnal dysfunction, and severe glomerular and tubulointerstitial
Ang II type 1 receptor (AT1R) antagonists and ACEIsinjury, whereas uninephrectomized control rats did not. There
reduce proteinuria and glomerulosclerosis in remnantwas a significant increase in the levels of glomerular protein
and cortical mRNA for TGF-b and collagen types I and III in kidney [14, 15] and hypertensive glomerulosclerosis mod-
els [16], suggesting that RAS plays an important role in
the occurrence of proteinuria and glomerulosclerosis inKey words: renin-angiotensin system, TGF-b, ACE inhibitors, bradyki-
nin, progressive renal disease. these models. However, the effect of the AT1R antago-
nist may not be entirely due to the blockade of AT1R.
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tensins may act on AT2R, which could have an antiprolif- room temperature (23 to 258C) with a 12-hour light/dark
erative effect [18] and, consequently, contribute to the cycle; the animals were allowed to eat standard feed
therapeutic effect of AT1R antagonist. (24% protein) and drink control water (distilled water)
Expansion of the mesangial area, caused by prolifera- ad libitum. Progressive mesangioproliferative GN was
tion or hypertrophy of mesangial cells accompanied by an induced, with minor modifications, according to a pre-
increase in the extracellular matrix, is a major pathological viously described protocol [28, 29]. Briefly, rats were
feature of glomerular diseases that often progress into uninephrectomized and, two weeks afterward, were in-
end-stage renal failure (ESRF) [19]. Accumulating evi- jected intravenously with 0.5 mg of anti-Thy-1 mono-
dence suggests that transforming growth factor-b (TGF-b) clonal antibody (MoAb 1-22-3). On the day when anti-
plays a pivotal role in the progression of renal disease [20, Thy-1 monoclonal antibody was injected, animals were
21]. Yamamoto et al reported that in a rat with progressive randomly assigned to five groups and were treated as
glomerulonephritis (GN) induced by two consecutive in- follows. The untreated group (N 5 6) comprised animals
jections of anti-Thy-1 antibody, TGF-b levels were ele- with nephritis and no treatment. The cilazapril-treated
vated by infiltrating platelets and macrophages in the group (N 5 6) comprised animals treated with the ACEI,
initial phase and were kept high by activated resident cilazapril (as powdered hydrochloride; Eizai, Tokyo, Ja-
glomerular cells in the late phase [22]. TGF-b autoin-
pan) in the drinking water. The concentration of cilaza-duces its own production, which greatly amplifies its bio-
pril was 10 mg/liter to allow administration of 1 mg/kglogical actions [23]. Ang II also increases the production
body wt/day of cilazapril, because the animals drankof TGF-b in cultured mesangial cells [24]. Glomerular
approximately 25 ml of water a day.hypertension increases the protein and mRNA levels of
The cilazapril plus Hoe 140-treated group (N 5 6)TGF-b in the glomerulus [25]. In contrast, nitric oxide
comprised animals treated with cilazapril and the brady-suppresses TGF-b increased by thromboxane in cultured
kinin B2-receptor antagonist, Hoe 140 (Hoechst AG,mesangial cells [26]. Ruiz-Ortega et al demonstrated that
Frankfurt, Germany), which was administered chroni-an ACEI attenuated the development of massive pro-
cally by subcutaneous infusion via osmotic minipumpsteinuria, ameliorated the morphological lesions, and de-
(Mini-osmotic pump model 2002; Alza Corp., Palo Alto,creased the gene expression of TGF-b and matrix pro-
CA, USA). The minipump filled with Hoe 140 was subcu-teins in rat immune-complex GN that morphologically
taneously implanted in the abdominal wall of the ratsresembles human mesangiocapillary GN, although it re-
under ether anesthesia, and a dose of 500 mg/kg bodymains unclear whether the renoprotective effect of ACEI
wt was injected daily [30]. The minipumps were replacedis due to the reduction of Ang II generation [27].
every two weeks.Recently, we reported a new animal model of progres-
sive mesangioproliferative GN with marked proteinuria, The candesartan-treated group (N 5 6) comprised
induced by a single intravenous injection of anti-Thy-1 animals injected intraperitoneally with 1 ml/kg body wt/
monoclonal antibody, MoAb 1-22-3, to uninephrectom- day of the AT1R antagonist candesartan (Takeda Chem-
ized rats [28]. Immunofluorescence (IF) studies revealed ical Industries, Osaka, Japan), which was solubilized in
an increase in glomerular expression of TGF-b in this phosphate-buffered saline (PBS; pH 7.2) at a concentra-
model. Furthermore, we have found that in this model, tion of 0.5 mg/ml to administer at 0.5 mg/kg body wt/
pirfenidone, an antifibrotic agent, decreased the glomer- day as previously described [31].
ular deposition of TGF-b and protected the kidney from The hydralazine-treated group (N 5 6) comprised ani-
the progression to ESRF [29]. These results, combined mals treated with hydralazine (as powdered hydrochlo-
with the findings mentioned earlier here [14–16, 27], ride; Ciba-Geigy Japan, Takarazuka, Japan) in the drink-
raised the possibility that in this model, RAS blockade ing water. The concentration of hydralazine was 50 mg/
could prevent the progression to ESRF by reducing the liter to allow administration of 5 mg/kg body wt/day.
production of TGF-b and matrix proteins. Therefore, us- The uninephrectomized control group (N 5 6) com-
ing this model, we investigated whether an ACEI and an prised animals injected with physiological saline instead
AT1R antagonist show renoprotective effects, whether a
of antibody.bradykinin type 2 receptor antagonist modifies the effect
To examine the effects of the repeated implantationsof an ACEI on the course of the disease, and whether
of the minipumps and daily intraperitoneal injectionsthese agents change the protein and mRNA levels of
on the progression of the disease, we performed theTGF-b and collagen types I and III.
following experiment. After uninephrectomized animals
were injected with antibody, they were randomly as-
METHODS signed to three groups and treated as follows.
Animals and protocol The minipump-implanted group (N 5 6) comprised
rats with a subcutaneously implanted minipump filledSix-week-old male Wistar rats (Japan SLC, Inc., Shizu-
oka, Japan) were housed in individual cages at a constant with PBS. The minipumps were replaced every two weeks.
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The PBS-injected group (N 5 6) comprised animals score previously described [34, 35]: grade 0, normal ap-
pearance; grade I, involvement of up to 25% of the glo-injected intraperitoneally with 1 ml/kg body wt/day of PBS.
The untreated group (N 5 6) comprised animals with merulus; grade II, involvement of 25 to 50% of the glo-
merulus; grade III, involvement of 50 to 75% of thenephritis and no treatment.
The uninephrectomized control group (N 5 6) com- glomerulus; grade IV, involvement of 75 to 100% of
the glomerulus. A glomerulosclerosis index (GSI) wasprised animals that were injected with physiological sa-
line instead of antibody. calculated by multiplying the number of glomeruli with
a sclerosis score of I by one, the number with a score of
Effect of treatment on the binding of antibody II by two, III by three, and IV by four. These values were
in the kidney summed and divided by the number of glomeruli assessed,
including those with a sclerosis score of zero. A minimumTo examine the effect of antihypertensive agents on
the binding of anti-Thy-1 monoclonal antibody to the of 150 glomeruli were examined from each specimen.
The tubulointerstitial lesion index (TILI; matrix deposi-glomeruli, we started the administration of candesartan
or cilazapril (three rats in each group) one day before tion and mononuclear cell infiltration) was assessed in
20 randomly selected cortical areas per sample and wasthe injection of 500 mg of 125I-labeled MoAb 1-22-3. These
animals were killed 30 minutes after injection, and radio- observed at a magnification of 3250 using the following
scale: 0 5 normal, 1 5 lesions involving less than 10%activity in the kidney was measured as previously de-
scribed [32], as this monoclonal antibody binds only to of the cortical area, 2 5 involving 10 to 30%, 3 5 involv-
ing 30 to 50%, and 4 5 involving more than 50%.the mesangial cells in the kidney [33]. MoAb 1-22-3 was
labeled with 125I by the chloramine-T method [34]. La- For the immunostaining for TGF-b and collagen types
I and III, kidney tissue was embedded in Tissue-Tektbeled preparations in which 98% of all isotopes were
protein bound were used. Specific activity was 45,673 O.C.T. compound (Sakura Finetek USA, Inc., Torrance,
CA, USA), snap-frozen in N-hexane cooled at 2708C,ct/min per mg of 125I-labeled MoAb. Radioactivity was
measured in an autogamma scintillation photometer and stored at 2708C until the study. Frozen tissues were
sectioned at 2 to 3 mm thickness using a cryostat. For(model 5260; Packard, Sterling, VA, USA).
the immunostaining for TGF-b, sections were pretreated
Proteinuria and renal function with acid urea, as described by Yoshioka et al [36], and
were incubated with rabbit anti-TGF-b antibody (a giftUrine was collected every two weeks from rats housed
for 24 hours in metabolic cages with access to water from Dr. Muramatsu, Research Center, Mitsubishi Kasei,
Yokohama, Japan; produced by the method describedonly. The amount of urinary protein (UProt) excreted was
measured by the Pyrogallol Red method. At the end of by Flanders et al [37]) for 30 minutes at room tempera-
ture. For the immunostaining for type I and III collagens,the study period, serum levels of creatinine were mea-
sured according to the standard method. Creatinine sections were washed in PBS and incubated with rabbit
antibodies against type I and III collagens (Chemiconclearance (CCr) was calculated from a urine sample taken
24 hours before the animal was sacrificed. International Inc., Temecula, CA, USA) for 30 minutes,
as previously described [38]. After being washed in PBS,
Blood pressure measurement the sections were incubated with fluorescein isothiocya-
nate-labeled antirabbit immunoglobulins (Dako, GlostrupSystolic blood pressure (SBP) was measured in con-
scious, restrained rats using a tail-cuff sphygmomanome- Denmark) for 30 minutes. The sections were washed in
PBS, mounted in buffered glycerol, and examined withter every two weeks after the induction of nephritis. The
SBP for each rat was calculated as the average of three an Olympus fluorescent microscope.
For each kidney, approximately 10 to 30 glomeruliseparate measurements at each session.
were assessed according to the degree of IF staining for
Kidney tissue processing TGF-b and collagen type I and type III. Glomerular
expression was graded semiquantitatively according toAt the time of sacrifice, animals were anesthetized
with ether. The kidneys were perfused in vivo via the the following procedure described by Kimura et al [39]:
0 5 no expression; 1 5 mild expression (less than 30%abdominal aorta with 50 ml of physiological saline at
48C, removed immediately, and processed further for of a glomerular area); 2 5 moderate expression (30 to
60% of a glomerular area); 3 5 marked expression (morehistologic studies and RNA extraction.
than 60% of a glomerular area). An expression score
Renal histologic studies was calculated by multiplying the number of glomeruli
with a expression score of 1 by one, the number with aTissue was fixed in buffered formalin and was embed-
ded in paraffin. Formalin-fixed tissue was sectioned (3 to score of 2 by two, and 3 by three. These values were
summed and divided by the number of glomeruli as-4 mm) and stained with periodic acid-Schiff. Glomerular
sclerosis was assessed as follows using a semiquantitative sessed, including those with an expression score of zero.
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Fig. 1. Time course of systolic blood pres-
sure. Symbols are: (j) untreated glomerulo-
nephritis (GN) rats; (r) hydralazine-treated
GN rats; (m) cilazapril-treated GN rats; (d)
cilazapril plus Hoe 140-treated GN rats; (h)
candesartan-treated GN rats; (s) nephrecto-
mized control rats. *P , 0.05 vs. untreated
GN rats.
Extraction of cortical total RNA and RESULTS
Northern blot hybridization Blood pressure
In three separate experiments, kidney tissue from two In untreated animals, the SBP increased gradually
animals was divided into the cortex and medulla portions, starting from six weeks after the induction of nephritis,
and cortical tissue was used for RNA isolation. Total and it was significantly elevated compared to the SBP
RNA from cortical tissue was extracted by the single- in nephrectomized controls (Fig. 1). Cilazapril, cilazapril
step method of Chomczynski and Sacchi [40]. Ten micro- plus Hoe 140, candesartan, and hydralazine significantly
grams of total RNA were separated by electrophoresis and equally prevented SBP from elevating, maintaining
on 1.0% agarose formaldehyde gels, transferred to a the SBP at the same level as that in nephrectomized
nylon filter (Hybond N), cross-linked by ultraviolet illu- control rats throughout the experiment.
mination, and hybridized with [32P]dCTP random-oligo- At the end of the experiment, SBP was significantly
labeled cDNA probes for rat TGF-b (a generous gift from elevated in animals in which a minipump was implanted
Dr. T. Nakamura) [41], rat a 1 (I) collagen (a generous subcutaneously, in those in which daily PBS was injected
gift from Dr. C. Genovese) [42], rat a 1 (III) collagen intraperitoneally, and in untreated nephritic animals
(a generous gift from Dr. Y. Yamada) [43], and GAPDH compared with SBP in nephrectomized control animals
(a generous gift from Dr. P. Fort) [44]. cDNA probes (Table 1).
were radiolabeled by random oligolabeling with DNA
Effect of antihypertensive agents on the binding of thepolymerase I (Takara Co. Ltd., Kyoto, Japan) in the
antibody to the kidneypresence of [32P]dCTP (3000 Ci/mmol). For hybridiza-
tion, the radiolabeled probe (total count, 106 cpm) and The amount of total kidney-fixing antibody from con-
100 ml (50 mg/ml) of salmon sperm DNA were added trol rats injected with 500 mg of MoAb 1-22-3 at 30
to this solution for 24 hours at 428C. The membranes minutes was 7.5 6 1.3 mg/kidney. Neither candesartan,
were washed three times. The radioautographs were cilazapril, nor hydralazine affected the binding of MoAb
quantitated by laser densitometry (Fujitsu Co. Ltd., Ky- 1-22-3 to the kidney (7.8 6 1.9, 7.8 6 1.7, 8.4 6 1.5
oto, Japan). mg/kidney, respectively). This result indicates that the
beneficial effects of Ang II blockade are not due to a
Statistical analysis decrease in the binding of the antibody to the kidney.
All values are expressed as the mean 6 standard error
Proteinuria, creatinine clearance, and body weightof the mean. For blood pressure and the urinary protein
excretion (UProt), statistical significance was evaluated There was no difference in 24-hour UProt among the
five groups before the induction of nephritis. As shownusing analysis of variance with modified t-tests. The semi-
quantitative evaluation of the immunostaining was com- in Figure 2, UProt significantly increased one week after
the induction of nephritis compared with that in nephrec-pared between groups with nonparametric analysis based
on the Kruskal–Wallis test. tomized control rats. In untreated animals, UProt increased
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Table 1. Effect of manipulations on UProt, CCr, SBP, and renal pathology in nephritic rats
UProt CCr SBP GSI TILI
PBS 130.3610.9 0.4660.14 16964 1.2660.13 2.1160.28
Minipump 135.367.2 0.4160.14 16064 1.4460.13 1.9860.28
Untreated 133.4610.7 0.6160.08 163614 1.4460.13 2.1860.36
Non-GN 13.861.0a 2.4760.32a 14364a 0.0760.01a 060a
Abbreviations are: UProt, 24 hour urinary protein excretion; CCr, creatinine clearance; SBP, systolic blood pressure; GSI, glomerulosclerosis index; TILI, tubulointersti-
tial lesion index. Data are expressed as mean 6 sem.
a P , 0.001 vs. untreated
Fig. 2. Time course of urinary protein excre-
tion. Symbols are: (j) untreated glomerulo-
nephritis (GN) rats; (r) hydralazine-treated
GN rats; (m) cilazapril-treated GN rats; (d)
cilazapril plus Hoe 140-treated GN rats; (h)
candesartan-treated GN rats; (s) nephrecto-
mized control rats. *P , 0.05 vs. untreated GN
rats; hsP , 0.05 vs. hydralazine-treated GN rats.
gradually until the end of the experiment. Cilazapril, treated, cilazapril plus Hoe 140-treated, and candesartan-
cilazapril plus Hoe 140, and candesartan decreased UProt treated GN animals were lower than those in nephrecto-
to control levels starting from two weeks after the induc- mized controls until six weeks after induction of the disease
tion of nephritis. Hydralazine failed to prevent the pro- and then became similar. Body weight did not differ among
gressive increase in UProt. GN animal groups until eight weeks after the induction
Creatinine clearance was significantly decreased in un- of disease. At 10 weeks after induction of disease, body
treated animals (0.60 6 0.12 ml/min/kg body wt) com- weight was lower in untreated and hydralazine-treated
pared with that in nephrectomized control animals (1.94 6 GN animals than in cilazapril-treated, cilazapril plus Hoe
0.13 ml/min/kg body wt, P , 0.0001). Cilazapril, cilazapril 140-treated, and candesartan-treated GN animals.
plus Hoe 140, and candesartan significantly increased cre- In minipump-implanted, PBS-injected, and untreated
atinine clearance to the control level (1.79 6 0.24, 1.93 6
groups, UProt was increased, and creatinine clearance was0.26, and 2.16 6 0.22 ml/min/kg body wt, respectively),
decreased compared with values in nephrectomized con-whereas hydralazine significantly increased creatinine
trol animals at the end of the experiment (Table 1).clearance (1.06 6 0.07 ml/min/kg body wt, P , 0.02),
Body weight was significantly lower in animals in whichbut not to the control level.
a minipump was implanted (288 6 7 g), in those in whichAll groups of animals gained body weight during the
PBA was injected daily intraperitoneally (286 6 7 g), andexperiment (Fig. 3). However, body weight was signifi-
in untreated nephritic animals (290 6 9 g) compared withcantly lower in untreated and hydralazine-treated GN
that in uninephrectomized control animals (331 6 6 g,animals compared with that in nephrectomized control
P , 0.05 vs. untreated GN rats). There were no signifi-rats starting from two weeks after induction of disease
to the end of the study. The body weights of cilazapril- cant differences in body weight among nephritic groups.
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Fig. 3. Time course of body weight. Symbols
are: (j) untreated glomerulonephritis (GN)
rats; (r) hydralazine-treated GN rats; (m) ci-
lazapril-treated GN rats; (d) cilazapril plus
Hoe 140-treated GN rats; (h) candesartan-
treated GN rats; (s) nephrectomized control
rats. *P , 0.05 vs. nephrectomized control rats.
Morphology not. Type I and type III collagens were mainly localized
in the mesangial area in more than 90% of glomeruliLight microscopy. Mesangial cell proliferation and
from untreated rats and segmentally in the mesangialmesangial matrix expansion were observed in more than
area of a few glomeruli from nephrectomized control90% of the glomeruli in untreated animals (Fig. 4). In-
rats. Cilazapril, cilazapril plus Hoe 140, and candesartanflammatory cell infiltration and fibrosis were also ob-
markedly reduced glomerular IF staining for collagensserved in the interstitium of untreated animals. Cilaza-
type I and type III, but not to the control level of nephrec-pril, cilazapril plus Hoe 140, and candesartan improved
tomized rats. Hydralazine did not change the glomerularthe pathological changes seen in untreated animals (Fig.
IF staining for type I and type III collagens.4), whereas hydralazine slightly improved the pathologi-
cal changes in untreated animals (Fig. 4). A semiquanti- Northern blot analysis
tative analysis showed that the GSI and TILI in untreated
Northern blot analysis showed that gene expressionanimals were high compared with values in nephrecto-
of TGF-b1 and collagens type I and III in untreated ratsmized controls (Fig. 5). Cilazapril, cilazapril plus Hoe
was increased compared with that in nephrectomized140, and candesartan markedly decreased GSI, but not
control rats (Fig. 11). Cilazapril, cilazapril plus Hoe 140,to the control level. Hydralazine decreased GSI and TILI
and candesartan reduced gene expression of these pro-slightly, but not significantly.
teins to control levels. Hydralazine also reduced gene
Neither subcutaneous minipump implantation nor daily
expression, but not to control levels.
intraperitoneal PBS injection influenced the morpholog-
ical changes seen in GN animals (Fig. 6 and Table 1).
DISCUSSION
Immunohistochemistry Several studies have attempted to compare the reno-
Representative glomeruli stained for TGF-b and colla- protective effects of ACEIs and AT1R antagonists [16,
gens type I and III are shown in Figures 7, 8, and 9. 45–47], and almost all have failed to distinguish any
Expression scores of TGF-b type I and III collagens are substantial differences in their effects, with some excep-
shown in Figure 10. TGF-b was mainly localized in the tions [48, 49]. ACEIs increase bradykinin concentrations,
mesangial area in more than 90% of the glomeruli from with sequential generation of nitric acid and prostaglan-
the untreated rats and segmentally in the mesangial area dins [7, 10], to which the beneficial effect of ACEIs
of a few glomeruli from nephrectomized control rats. may be attributed. AT2R has been shown to exert an
Cilazapril, cilazapril plus Hoe 140, and candesartan re- antiproliferative effect [18], which may contribute to the
duced glomerular IF staining for TGF-b to the level of beneficial effect of AT1R antagonists. Because of the
possibility that bradykinin and pathways mediated bynephrectomized control rats, although hydralazine did
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Fig. 4. Light micrographs of a glomerulus from untreated glomerulonephritis (GN) rats (A), hydralazine-treated GN rats (B), cilazapril-treated
GN rats (C), cilazapril plus Hoe 140-treated GN rats (D), candesartan-treated GN rats (E ), and nephrectomized control rats (F ) (PAS stain final
magnification 3560).
AT2R may contribute to the renoprotective effects of an AT1R antagonist with respect to renoprotective ef-
fects and examined the effect of a B2 receptor antagonistACEIs and AT1R antagonists, respectively, to the same
extent, we cannot conclude that the renoprotective effect on ACEI-induced renoprotection in rat mesangioproli-
ferative GN.of ACEIs is mediated by the reduction of Ang II genera-
tion, even if ACEIs and AT1R antagonists show the Because we started the treatment on the same day
that antibody was injected, it seems possible that Angsame beneficial effect. Thus, we compared an ACEI with
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Fig. 5. Glomerulosclerosis index (GSI) and
tubulointerstitial lesion index (TILI) in exper-
imental nephritis. Symbols are: (h) untreated
glomerulonephritis (GN) rats; ( ) hydrala-
zine-treated GN rats; ( ) cilazapril-treated
GN rats; ( ) cilazapril plus Hoe 140-treated
GN rats; ( ) candesartan-treated GN rats;
(j) nephrectomized control rats. *P , 0.001
vs. untreated GN rats; hsP , 0.05 vs. hydrala-
zine-treated GN rats; †P , 0.005; #P , 0.05
vs. uninephrectomized control.
Fig. 6. Light micrographs of a glomerulus from untreated (A), daily intraperitoneally phosphate-buffered saline injected (B), subcutaneously
minipump implanted (C) glomerulonephritis (GN) rats, and non-GN control rats (D) (PAS stain; final magnification, 3560).
II blockades ameliorate nephritis by changing the bind- antibody in the kidney. We also found that antihyperten-
sive agents did not ameliorate the increase in proteinuriaing of the antibody in the kidney. To exclude this possibil-
ity, we examined the effect of antihypertensive agents one week after induction of the disease. These results
indicate that antihypertensive agents did not affect theon the binding of antibody in the kidney and found that
antihypertensive agents did not change the binding of induction of the disease by changing the binding of anti-
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Fig. 7. Immunofluorescence micrographs of a glomerulus stained with anti-TGF-b antibody. (A) indicates untreated glomerulonephritis (GN)
rats, (B) hydralazine-treated GN rats, (C) cilazapril-treated GN rats, (D) cilazapril plus Hoe 140-treated GN rats, (E ) candesartan-treated GN
rats, (F ) nephrectomized control rats (final magnification 3350).
Fig. 8. Immunofluorescence micrographs of a glomerulus stained with antitype I collagen antibody. (A) indicates untreated glomerulonephritis
(GN) rats, (B) hydralazine-treated GN rats, (C) cilazapril-treated GN rats, (D) cilazapril plus Hoe 140-treated GN rats, (E ) candesartan-treated
GN rats, (F ) nephrectomized control rats (final magnification 3350).
body in the kidney. We also used daily intraperitoneal body weight among the GN animal groups until six weeks
after induction of the disease, suggesting that manipula-injections of candesartan and repeated subcutaneous
minipump implantations to administer Hoe 140. To ex- tions did not change the nutritional condition among the
GN animal groups.clude the possibility that these manipulations could
change the course of the disease, we examined the effects An in vitro study using isolated interlobular, efferent,
and afferent arteriolar preparations demonstrated thatof manipulations and found that they did not affect the
progression of the disease. There was no difference in bradykinin causes marked vasodilation only in the effer-
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Fig. 9. Immunofluorescence micrographs of a glomerulus stained with antitype III collagen antibody. (A) indicates untreated glomerulonephritis
(GN) rats, (B) hydralazine-treated GN rats, (C) cilazapril-treated GN rats, (D) cilazapril plus Hoe 140-treated GN rats, (E ) candesartan-treated
GN rats, (F ) nephrectomized control rats (final magnification 3350).
Fig. 10. Semiquantatative evaluation of im-
munohistochemistry in experimental glomer-
ulonephritis. Symbols are: (h) untreated glo-
merulonephritis (GN) rats; ( ) hydralazine-
treated GN rats; ( ) cilazapril-treated GN
rats; ( ) cilazapril plus Hoe 140-treated GN
rats; ( ) candesartan-treated GN rats; (j)
nephrectomized control rats. *P , 0.01 vs.
untreated GN rats; hsP , 0.01 vs. hydralazine-
treated GN rats; #P , 0.01 vs. uninephrectom-
ized control.
ent arteriole [9]. Both bradykinin type 1 (B1) and type 2 generation and/or maintenance of renal vasoconstriction
in disease states that lead to ESRF [54]. The B2 receptor(B2) receptors have been identified in the glomerulus
[50, 51]. The B1 receptor has a selective affinity for the is thought to mediate most of the physiological functions
of bradykinin [9, 10], including vasodilation, diuresis,natural metabolite des-Arg9-bradykinin [52]. Bradykinin
should predominantly be degraded into des-Arg9-brady- and formation of nitric oxide and prostacyclin. These
findings suggest that if an ACEI-induced increase in bra-kinin under pathological conditions [51]. Collagen syn-
thesis and cell proliferation are induced through the B1 dykinin is involved in preventing the progression to
ESRF, it should be mediated through the B2 receptor.receptor in rat mesangial cells [53]. The B1 receptor
responses have been reported to be important in the Previous studies demonstrated that Hoe 140 is specific
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an ACEI, but not an AT1R antagonist, reduced protein-
uria [13], while aprotinin, a blocker of bradykinin produc-
tion, blunted the antiproteinuric effect of ACE inhibition
[12]. These results suggested that the antiproteinuric ef-
fect of ACEIs is mediated by an increase in bradykinin.
Tanaka et al examined the mechanism by which an ACEI
decreases proteinuria in puromycin aminonucleoside-in-
duced nephrosis [47]. They found that ACEIs lessened
proteinuria by increasing bradykinin in the early phase
and by decreasing Ang II generation in the late phase.
In addition, they demonstrated that enalapril and an
AT1R antagonist improved the renal pathology, and
they speculated that the subsequent progression of glo-
merulosclerosis is caused by the RAS-involving mecha-
nism. This study demonstrated that proteinuria increases
sharply one week after induction of the disease and then
gradually increases until the end of the study. Cilazapril
and candesartan did not reduce the early phase protein-
uria, but did reduce the late-phase proteinuria. Hoe 140
did not abolish the ACEI-induced reduction of the late-
phase proteinuria. The results suggest that the early-
phase proteinuria is independent of Ang II and bradyki-
nin, and that the late-phase proteinuria is due to the
RAS-involving mechanism. This study also showed that,
in contrast to hydralazine, RAS blockades produced the
renoprotective effect, whereas RAS blockades and hy-
dralazine failed to reduce the early phase proteinuria,
suggesting that the renoprotective effect of a treatment
cannot be predicted by whether the treatment reduces
proteinuria in the early phase.
The participation of TGF-b in the progression of glo-
Fig. 11. (A) Northern blot analysis. Typical autoradiograms of mRNA merulosclerosis was shown by the in vivo and in vitro
for TGF-b (2.5 kb), collagen I (4.7 and 5.7 kb), collagen III (5.3 kb) studies of Border et al [20–22, 24, 58]. Ang II increasesfrom the renal cortex of experimental glomerulonephritis (GN) rats.
protein and mRNA levels of TGF-b and matrix compo-(B) Renal cortical mRNA levels for TGF-b, collagen I (col. I), and
collagen III (col. III). Symbols are: (h) untreated GN rats; ( ) hydra- nents in cultured mesangial cells [24]. Our study showed
lazine-treated GN rats; ( ) cilazapril-treated GN rats; ( ) cilazapril that protein and mRNA levels of TGF-b and collagenplus Hoe 140-treated GN rats; ( ) candesartan-treated GN rats; (j)
types I and III increased in our model and that Ang IInephrectomized control rats. *P , 0.01 vs. untreated GN rats; hsP ,
0.01 vs. hydralazine-treated GN rats; #P , 0.01 vs. uninephrectomized blockades, but not hydralazine, reduced these signals and
control. ameliorated the disease. The results suggest that RAS
blockades prevent the progression of the disease by reduc-
ing TGF-b synthesis. On the other hand, Shimizu et al
found that pirfenidone decreased mRNA levels of TGF-bfor kinin B2 receptors and does not influence the actions
of other vasoactive hormones such as prostaglandins, and ameliorated renal pathology, but failed to reduce
proteinuria in a rat remnant kidney model [59]. In addi-norepinephrines, and Ang II [55–57]. Cilazapril and can-
desartan, but not hydralazine, reduced proteinuria and tion, our previous study with progressive mesangioprolif-
erative GN showed that pirfenidone significantly reducedameliorated the morphological lesions, although cilaza-
pril, candesartan, and hydralazine reduced SBP to the proteinuria, but not to the control levels [29]. ACEIs
produce greater vasodilation in efferent arterioles, andsame extent. Hoe 140 failed to blunt the cilazapril-induced
renoprotection. These results suggest that most of the these hemodynamic changes reduce the intraglomerular
pressure, resulting in the reduction of proteinuria andbenefits conferred by cilazapril are achieved through the
reduction of AT1R-mediated effects of Ang II and that in renoprotection [60]. Cyclic stretching of cultured mes-
angial cells that may occur in response to glomerularneither kinin potentiation nor AT2R-mediated pathways
contribute to the beneficial effect of RAS blockades in hypertension leads to increased synthesis of matrix pro-
teins and TGF-b [61, 62]. Taken together, it seems likelythis model.
In the nephrotic phase of passive Heymann nephritis, that RAS blockades prevent the progression of the dis-
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activity in acute renovascular hypertension. Renal Physiol 10:311–ease not only by reducing the production of TGF-b and
317, 1987
matrix components, but also by modulating intrarenal 7. Campbell DJ, Kladis A, Duncan A-M: Effects of converting
enzyme inhibitors on angiotensin and bradykinin peptides. Hyper-hemodynamics.
tension 23:439–449, 1994In summary, we have demonstrated that (a) in progres-
8. Johnston CI, Clappison BH, Anderson WP, Yasujima M: Effect
sive mesangioproliferative GN, an ACEI and an AT1R of angiotensin-converting enzyme inhibition on circulating and
local kinin levels. Am J Cardiol 49:1401–1404, 1982antagonist, but not hydralazine, attenuate the develop-
9. Edwards RM: Response of isolated renal arterioles to acetylcho-ment of massive proteinuria, ameliorate morphological
line, dopamine, and bradykinin. Am J Physiol 248:F183–F189, 1985
lesions, and reduce the protein and mRNA levels of 10. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA: Contri-
bution of kinins to the cardiovascular actions of angiotensin-con-TGF-b1 and collagens type I and III, and that (b) Hoe
verting enzyme inhibitors. Lab Invest 47:25–48, 1995140 did not blunt the ACEI-induced renoprotection. 11. Hutchison FN, Schambelan M, Kaysen GA: Modulation of albu-
These findings suggest that ACEIs prevent the progres- minuria by dietary protein and converting enzyme inhibition. Am
J Physiol 253(Renal Fluid Electrolyte Physiol 22):F719–F725, 1987sion to ESRF by modulating the effects of Ang II via
12. Hutchison FN, Martin VI: Effects of modulation of renal kalli-AT1R on the production of TGF-b and matrix compo- krein-kinin system in nephrotic syndrome. Am J Physiol 258(Renal
nents as well as on intrarenal hemodynamics in this rat Fluid Electrolyte Physiol 27):F1237–F1244, 1990
13. Hutchison FN, Webster SK: Effect of ANG II receptor antagonistmodel of progressive GN.
on albuminuria and renal function in passive Heymann nephritis.
Am J Physiol 263(Renal Fluid Electrolyte Physiol 32):F311–F318,
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